CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
33.14
-0.89 (-2.62%)
At close: Apr 1, 2025, 4:00 PM
33.48
+0.34 (1.03%)
After-hours: Apr 1, 2025, 7:57 PM EDT

CRISPR Therapeutics AG Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Net Income
-366.25-153.61-650.18377.66-348.87
Upgrade
Depreciation & Amortization
19.2619.8424.1717.959.18
Upgrade
Asset Writedown & Restructuring Costs
-2.5---
Upgrade
Stock-Based Compensation
86.5781.0397.95102.3966.02
Upgrade
Other Operating Activities
-38.62-16.5512.4714.111.86
Upgrade
Change in Accounts Receivable
175-2000.31-0.16-0.05
Upgrade
Change in Accounts Payable
-27.28-20.255.1637.5125.75
Upgrade
Change in Unearned Revenue
-1.955.79-1.01-0.781.38
Upgrade
Change in Other Net Operating Assets
10.520.8715.39-9.716.36
Upgrade
Operating Cash Flow
-142.77-260.38-495.74538.97-238.37
Upgrade
Capital Expenditures
-1.9-9.47-37.19-81.71-18.36
Upgrade
Sale (Purchase) of Intangibles
--2.5---
Upgrade
Investment in Securities
-278.58386.62-221.47-953.73-522.81
Upgrade
Investing Cash Flow
-280.48374.65-258.66-1,035-541.17
Upgrade
Issuance of Common Stock
331.9862.6638.59250.951,016
Upgrade
Financing Cash Flow
331.9862.6638.59250.951,016
Upgrade
Foreign Exchange Rate Adjustments
-0.020.07-0.08-0.010.04
Upgrade
Miscellaneous Cash Flow Adjustments
--0---
Upgrade
Net Cash Flow
-91.29177.01-715.88-245.52236.66
Upgrade
Free Cash Flow
-144.68-269.85-532.93457.27-256.72
Upgrade
Free Cash Flow Margin
-387.72%-72.69%-44484.89%49.98%-35705.70%
Upgrade
Free Cash Flow Per Share
-1.72-3.41-6.865.69-3.89
Upgrade
Levered Free Cash Flow
-29.27-238.97-337.58284.82-112.91
Upgrade
Unlevered Free Cash Flow
-29.27-238.97-337.58284.82-112.91
Upgrade
Change in Net Working Capital
-158.41188.781.78-12.73-51.77
Upgrade
Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q